| New from NCI |
| Video—Steps to Find a Clinical Trial |
 |
|
The new video on this page illustrates how to use our six-step guide to help you find a treatment clinical trial. |
| HPV Vaccination Linked to Decreased Oral HPV Infections |
 |
|
New study results suggest that the human papillomavirus (HPV) vaccine may sharply reduce oral HPV infections that are a major risk factor for oropharyngeal cancer, a type of head and neck cancer. |
| Less Chemotherapy May Be Best Choice for Some Patients with Colon Cancer |
 |
|
Recent trial results suggest that a shorter course of chemotherapy following surgery may be enough for patients at low risk of disease recurrence. |
|
PSA Test Fact Sheet Updated
The prostate-specific antigen (PSA) test fact sheet has been revised to reflect the latest guidance from the U.S. Preventive Services Task Force.
|
|
Asbestos Exposure and Cancer Risk Fact Sheet Updated
This fact sheet has been updated. Learn what asbestos is and how it relates to the risk for cancer and other diseases.
|
|
Clinical Trial Seeks to Determine if Two Targeted Drugs Are Better Than One
This ongoing clinical trial is enrolling patients with newly diagnosed metastatic non-small cell lung cancer that tests positive for a mutation in the EGFR gene. Doctors want to know if combining afatinib with cetuximab improves survival better than afatinib alone for these patients.
|
|
FDA Expands Approval of Pembrolizumab for First-Line Treatment of Non-Small Cell Lung Cancer
The Food and Drug Administration (FDA) approved the immune checkpoint inhibitor pembrolizumab to be used with chemotherapy as a first-line treatment for non-small cell lung cancer.
|
| PDQ Summary Updates |
|
Nausea and Vomiting Related to Cancer Treatment
We updated our PDQ summary on cancer-related nausea and vomiting with major revisions to all sections of the summary.
|
| Drug Information Updates |
|
New Approval for Microsatellite Instability-High Cancer
We’ve updated our pembrolizumab drug summary to include a recent approval from FDA. Pembrolizumab is now approved to treat solid tumors with certain genetic features: mismatch repair deficiency and high microsatellite instability. Tumors with these genetic mutations may not respond to some types of treatment.
|
